Form D · Pharmaceuticals
Nuro Pharma Inc
Las Vegas, NV · CIK 0001552958
Offering snapshot reported Jun 19, 2013 · SEC filing
- Reported sold
- $80K Offering amount: $510K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jun 5, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 19, 2013 | Initial | $79,992 | No comparison | 1 | SEC filing |
| Jul 11, 2012 | Amendment | $658,392 | $0vs Jul 10, 2012 | 6 | SEC filing |
| Jul 10, 2012 | Initial | $658,392 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06, 46
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-198272
Offering is expected to terminate on October 30, 2013
Source: Form D, filed Jun 19, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Fares | Director, Executive, Promoter |
| Albert Hansen | Director, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6380 Polaris Ave Unit B
Las Vegas, NV, 89118
Las Vegas, NV, 89118